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ABSTRACT 
 
Development of Neuronal Cell Type Inducible GM-CSF Gene Expression 
System and Combined Cell Therapy in Spinal Cord Injury Model 
 
Youngsang You 
 
Department of Medical Science 
The Graduate School, Yonsei University 
 
(Directed by Professor Yoon Ha) 
 
Promising therapy is needed to treat spinal cord injury (SCI) associated with 
permanent neurological damage. It is difficult to expect a sufficient therapeutic 
outcome by a single treatment method. Therefore, a strategy combining two or more 
techniques might be better for improving therapeutic effects. 
In this study, it was designed that a merged treatment strategy using neural stem 
cells (NSCs) introduced with neuronal cell-type inducible transgene expression 
system controlled by a neuronal specific enolase (NSE) promoter to maximize the 
therapeutic efficiency. The luciferase gene was chosen to confirm whether this 
combined system was working properly prior to using a therapeutic gene. The 
luciferase expression levels of NSCs introduced with a neuronal cell-type inducible 
luciferase expression system (NSE-Luci) or with a general luciferase expression 
system (SV-Luci) were measured and compared in vitro and in vivo. 
After verified neuronal cell-specific gene expression by luciferase gene, therapeutic 
gene, GM-CSF, was substituted with luciferase gene. Neuronal cell type-inducible 
GM-CSF expression system (NSE-GMCSF) compared with a general GM-CSF 
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expression system (SV-GMCSF) in vitro and in vivo.  
The results show that neural stem cells introduced with a neuronal cell-type 
inducible luciferase expression system (NSE-Luci) showed a high level of luciferase 
expression compared to neural stem cells introduced with a general luciferase 
expression system (SV-Luci). And also therapeutic gene system, a neuronal cell-type 
inducible GM-CSF expression system (NSE-GMCSF) was higher expressed GM-CSF 
than a general GM-CSF expression system (SV-GMCSF).  
A neuronal cell-type inducible gene expression system has been demonstrated that 
it’s suitable for NSCs in a merged-treatment strategy. Therefore, it is suggested that 
this merged-treatment strategy based on NSCs and a neuronal cell-type–inducible 
gene expression system is a promising tool for treatment of neurodegenerative 
disorder, including SCI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key words: Neuronal specific enolase (NSE), Granulocyte-macrophage colony-
stimulating factor (GM-CSF), Neuronal cell-type inducible transgene expression, 
Neural stem cells (NSCs), Merged treatment strategy, Spinal cord injury (SCI) 
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I. INTRODUCTION 
Spinal cord injury (SCI) is often associated with permanent disability as a result of 
sensory or motor functional defects caused by neuronal death and demyelination after 
primary physical damage.1 A single treatment strategy is unlikely to result in 
complete recovery. Therefore, a merged-treatment method might be effective for 
improving the therapeutic efficacy. In the field of gene therapy, therapeutic gene 
expression controlled by hypoxia-specific or tissue-specific gene expression systems 
offers a possibility for efficient and safe gene therapy.2-6  
In the stem cells therapy field, transplantation with neural stem cells (NSCs) showed 
therapeutic potential in animal models with incurable disorders, including SCI.7,8 
Interestingly, it has been reported that stem cells can be used as a gene delivery 
system,9 and stem cell-mediated gene therapy resulted in a better therapeutic outcome 
and more stable therapeutic gene delivery than single therapy with stem cells or 
therapeutic genes alone.10-13  
Granulocyte-macrophage colony-stimulating factor (GM-CSF), synonym is colony 
stimulating factor (CSF2), which is also known as a hematopoietic factor and is a 
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14.2kDa globular protein structure secreted by macrophages, T cell, mast cells, NK 
cells, endothelial cell and fibroblasts.14 GM-CSF is 125 amino acids and is essential 
for the in vitro proliferation and differentiation of precursor cells into mature 
granulocyte and macrophage.15 
GM-CSF recruited monocytes and macrophage and convert to their mature form.16 
After mature macrophages are transfer to a lesion site, they remove the debris that 
interferes with neuronal regeneration.17 GM-CSF is possible to pass through the 
blood-brain barriers or blood-cerebrospinal-fluid barriers so that GM-CSF is 
potentially pharmacological material for the treatment of CNS injury.18 The results in 
many previous studies were shown that GMCSF not only regulates formation of glial 
scar, also promotes survival of neuronal cells in vitro and in SCI and Parkinson’s 
disease model.19-23 Anti-apoptotic effect of GMCSF was also demonstrated in clinical 
study.24,25 Based on the results of previous research, GM-CSF was chosen as a 
therapeutic gene to combine with the neuronal cell type-inducible gene expression 
system. 
Considering that most stem cell therapies for SCI have used neural stem cells or 
neural precursor cells, which have high neuronal differentiation potentials, the neuron 
specific enolase (NSE) promoter was chosen for transgene over-expression in neural 
stem cells which have it considerably. It was assumed that a combined treatment 
strategy based on NSCs which were controlled by NSE promoter would increase 
therapeutic efficiency and neural differentiation. Finally, it was demonstrated that an 
NSE promoter is suitable with NSCs for the establishment of a gene and neural stem 
cell therapy platform.   
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II. MATERIALS AND METHODS 
1. Plasmid construction 
A neuronal cell type-inducible luciferase expression system (NSE-Luci) and a 
general luciferase expression system (SV-Luci) were made by pGL3 luciferase 
reporter vectors to verify that the NSE with mNSCs was suitable for a merged therapy 
strategy. SV-Luci was purchased from Promega (Madison, WI, USA, Cat.no E1761). 
Neuron-specific enolase promoter was provided by Professor Lee (Hanyang 
University, Seoul, Korea). The NSE region was inserted between NheI and BglII sites 
of a pGL3-basic vector (Promega, Cat.no E1751). 
Another experiment 2, SV-GMCSF and NSE-GMCSF vector were made by a 
backbone of SV-Luci and NSE-Luci vectors. The Luciferase gene was replaced by 
mouse GM-CSF (Sino biological Inc., Beijing, China). The construction designs of 
the plasmids are shown in Fig. 1A. 
 
2. Cell culture 
Mouse neural stem cells (mNSCs) were used in this study. mNSCs (CRL-2925, 
ATCC, Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) / F12 and supplemented with 10 % Fetal Bovine Serum (FBS; Thermo 
Scientific HyClone, Logan, UT, USA), and 1 % penicillin and streptomycin 
(Invitrogen, Carlsbad, CA, USA). Approximately, 4×104 cells/cm2 were seeded with 
culture media. the culture dishes were incubated at 37 ℃ in a humidified atmosphere 
containing 5 % CO2. 
For the other experiment, we used the human embryonic kidney cells (HEK 293FT) 
which were provided from Professor Kang (Yonsei University, Seoul, Korea). Cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 
10 % FBS, 1 % Penicillin and Streptomycin, 1 X Non-Essential Amino Acid (NEAA, 
Invitrogen) and 1 X Sodium pyruvate (Invitrogen). Approximately 6×105 cells were 
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plated in 6-well culture dishes (6×104 cells/cm2) and incubated at 37 °C in a 
humidified atmosphere containing 5 % CO2. 
 
3. Gene transfection 
Only transient gene expression method was used throughout the experiment. To 
generate transfected mNSCs, plasmid vectors (4 μg DNA per well) were used with 
Lipofectamine 2000 (10 μl per well; Invitrogen, Carlsbad, CA, US) or ViafectTM  (10 
μl per well : Promega, Madison, WI, USA).  
Before experiments were conducted, the transfection efficiency into mNSCs was 
tested. mNSCs (approximately 2×104 cell/cm2) were seeded with a mixture of DsRed 
plasmid /ViafectTM) in a 6-well plate, then incubated under normal conditions (pO2, 
21 %, 37 ) for 48 h℃ . DsRed and DAPI positive cells were counted. 
In the first experiment, approximately, 2×104 cells/cm2 mNSCs were seeded with a 
mixture of plasmids/Lipofectamin with DMEM/F12 media in a 6 well plate and 
incubated under normal condition (pO2, 21 %). The day after transfection, culture 
media was changed and incubated in hypoxia condition (pO2, 1 %) during 24 h. Over-
expression of transfected gene was demonstrated by luciferase assay and IVIS image. 
In the second experiment, GM-CSF expression, approximately 2×104 cells/cm2 of 
mNSCs were seeded with mixture of plasmids/ViafectTM with DMEM/F12 media in a 
6 well plate and incubated in 37 ℃ for 48 h. Like a first experiment in hypoxia 
condition, transfected cells were incubated in hypoxia chamber, with or without 
DMSO, in 24 h from the day after transfection. After total 48 h, GM-CSF expression 
was determined by using supernatant of media with the mouse GM-CSF ELISA kit. 
Whether the levels of expression of GM-CSF were sustained, mNSCs (approximately 
2×104 cells/cm2) were seeded in a 6-well plate and transfected with a mixture of 
transfection reagent and each group of vectors (Control, SV-GMCSF, and NSE-
GMCSF). The supernatant was harvested at 3, 5, and 7 days after transfection. The 
amount of GM-CSF secreted in culture media was measured using the mouse GM-
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CSF ELISA kit. 
 
4. Neural differentiation 
For inducing of neural differentiation, mNSCs were cultured in presence of retinoic 
acid (RA, sigma, USA) for 7 days. RA was dissolved in DMSO (working solution, 10 
mM), and diluted with culture media (final concentration, 1 μM). Briefly, mNSCs 
were seeded on poly-L-lysine (2 μg/cm2, Sigma, StLouis, MO, USA) – coated glass 
cover slips at a density of 2×104 cells/cm2, and then transfected with the plasmid. 
After 24 h incubation, the medium was replaced with a complete medium with or 
without RA and then changed every 2 days. Neural differentiation was carried out for 
7 days. 
 
5. Cell transplantation 
All protocols were approved by the Animal Care and Use Committee of the Medical 
Research Institute at Yonsei University College of Medicine. All experiments were 
conducted in accordance with international guidelines on the ethical use of animals, 
and the number of animals used was minimized. ICR mice (male, 6 weeks, 30 g, 
OrientBio, Gyeonggi-do, Korea) were intraperitoneally injected with Ketamine (100 
mg/kg, Yu-han, Seoul, Korea), and Rompun (10 mg/kg, Bayer Korea, Seoul, Korea) 
for anesthetization. Laminectomy was performed at thoracic level 11. Spinal cord 
injury was carried out using a self-closing forcep (compression injury for 10 sec).  
7 days after SCI, animals were anesthetized and transfected mNSCs of each group 
were transplanted into a lesion of a spinal cord. At the experiment 1, mNSCs of each 
group were prepared by conducting transfection with SV-Luci and NSE-Luci at the 
day before for transplantation. At the experiment 2, all mice were randomly divided 
into 4 groups : Sham (only SCI) and Control (Ds-Red), SV-GMCSF and NSE-
GMCSF.  
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mNSCs of all groups were transplanted to spinal cords for 2 min (5×105 cells in a 2 
μl volume) using a micro-injector pump (KDS310; KD Scientific, US). The exposure 
site was sealed using suture wound clips and Cyclosporine A (10 mg/kg) and 
Cefazolin (20 mg/kg, Yu-han) were injected into mice daily until being sacrificed. 
Mice were sacrificed within 1 day after transplantation to detect a gene expression 
and sacrificed 4 days to conduct western blotting. 
 
6. In Vivo Imaging System (IVIS) 
The IVIS Spectrum (Xenogen, Alameda, CA, USA) was used to detect luciferase 
expression. For in vivo imaging, mice were anesthetized with ketamine (100 mg/kg) 
and Rompun (10 mg/kg), and then the substrate D-luciferin (150 mg/kg) was injected 
intraperitoneally. Twenty minutes after injection, bioluminescence images were 
captured for 10 min. Regions of interest (ROIs) were analyzed and total quantification 
of bioluminescence was quantified using Living Image® (Xenogen) software. For in 
vitro imaging, the substrate D-luciferin (150 μg/ml) was added to the Control (DsRed), 
SV-Luci, and NSE-Luci in medium, followed by mounting and bioluminescence 
detection for 2–3 min. 
 
7. Luciferase Assays 
Transfected cells were harvested and lysed with Pro-prepTM (iNtRON biotechnology, 
Gyeonggi-do, Korea) adding 400 μl for in vitro transfection assay. The concentrations 
of the extracted protein were measured by using BCA protein assay kit (Pierce, Iselin, 
NJ) and amount of luciferase expression was detected by using Luminometer by 
relative light units (RLU) for 10 sec. the level of luciferase expression was presented 
by RLU per mg of total protein. For ex vivo assay, anesthetized animals were 
conducted perfusion with PBS and immediately extracted that spinal cord segments at 
4 mm rostral and caudal of the transplanted region. Samples were transferred to the 
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micro centrifuge and then lysed with lysis buffer 400 μl for 1 h and centrifuged at 
13,000 rpm for 10 min. The supernatant was poured into other tubes and measured the 
quantity of extracted protein and the level of luciferase expression. 
 
8. ELISA Assay 
To detect levels of secreted GM-CSF in spinal cords, a kit of mouse GM-CSF 
ELISA (Young-In Frontier Inc., Seoul, Korea) was used. Before using the ELISA kit, 
the samples were prepared with collecting sample media in vitro. supernatant of 
media was separated by centrifuging at 2,000 × g for 10 min at 4 ℃ and stored at   
–20 ℃ until testing took place. 
For in vivo model, to detect the level of secreted GM-CSF in spinal cords, all spinal 
cords were removed after saline perfusion to eliminate blood, and temporarily stored 
at –70 .℃  Before conduct ELISA, spinal cord samples were lysed with 400 μl Pro-
prepTM for 1 h to extract protein. Extracted proteins were used to ELISA assay and 
total concentrations of the extracted protein were measured using BCA protein assay 
kit. ELISA assay was conducted following the manufacturer’s protocol. Standard and 
samples of serum or supernatant media (100 μl per well) were added to the plate and 
incubated for 2 h at room temperature. Then secondary antibody solution and 
streptavidin HRP solution were added to each well and incubated for 1h. Before 
starting each step, washing the well was conducted 3 times. After substrate were 
added into each well, stop solution were add in 5 min. ELISA assay was measured by 
using the ELISA reader (VERSAmax, Molecular Devices, Sunnyvale, CA, USA). 
The values of the sample’s optical density (OD) were detected at 450 nm. 
 
9. Immunocytochemistry 
Differentiated cells were fixed in 4 % paraformaldehyde, pH 7.4 (Merck, Darmstadt, 
Germany), for 10-15 min at RT. Samples were washed with phosphate buffered saline 
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(PBS, Thermo) three times. Blocking was performed with 10 % normal donkey serum 
in PBS containing 0.3 % Triton X-100 for 60 min at RT. Primary antibodies against 
beta-III-Tubulin (TUJ1), microtubule-associated protein 2 (MAP2), neural cell 
adhesion molecule (NCAM), Luciferase and neuro-filament heavy (NF-H) were 
incubated overnight at 4 °C. Samples were washed three times with PBS, and 
secondary antibodies were added and incubated for 1 h at RT. Samples were washed 
three times with PBS, and 4’, 6’-diamino-2-phenylinodole (DAPI; Vector Labs, 
Burlingame, CA, USA) was added. Samples were covered with glass coverslips. A 
laser confocal microscope (LSM 700; Zeiss, Oberkochen, Germany) was used for 
analysis. 
 
10. Western blotting 
Western blotting was conducted to determine the function of the therapeutic gene 
GM-CSF. All of the extracted tissue lysates were prepared and loaded onto SDS-
PAGE gels (10-12 % gel, Bio-Rad, Richmond, CA, USA). After electrophoresis, 
transferring and blocking, primary antibodies targeting Bax (dilutions of 1:1,000, 
Millipore Corp., Milford, MA, USA) and -actin (1:10,000, Abcam, Cambridge, UK) 
were applied. After conjugation of secondary antibodies, detection of protein signals 
was performed with the automatic X-ray film processor (TM-300E; TAEAHN Inc, 
Incheon, Korea), and densitometry was quantified using ImageJ (NIH, Bethesda, MD, 
USA). 
 
11. Cell viability assay 
The protective effect of GM-CSF was measured in 96-well plates by using the MTT 
assay. mNSCs were seeded at a density of 0.5×104/cm2 and incubated for 3 days with 
supernatant media from each group (Control, SV-GMCSF, NSE-GMCSF) and treated 
with a chemically toxic reagent (diluted in 1 % DMSO) for an additional 24 h. MTT 
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reagent (final concentration of 0.5mg/ml; Sigma) was added to each well. After 3 h, 
the viability of cells was measured using the ELISA reader (VERSAmax) at 562 nm. 
 
12. Statistical analysis 
Statistical analysis was performed using Prism 6 (Graphpad, San Diego, CA, USA) 
and MedCalc software version 14.12.0 (MedCalc, Mariakerke, Belgium). All data 
were evaluated using Student’s t-test and a one-way ANOVA followed by the Tukey-
Kramer Post hoc test. All data are expressed as the mean ± standard error of the mean 
(S.E.M). A P-value < 0.05 was considered statistically significant.   
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Table 1. List of Antibodies used in the whole experiments 
Antibody Host 
Product Information Dilution 
Factor Company Cat.No 
MAP2 Mouse Abcam AB11267 1:500 
MAP2 Rabbit Abcam AB32454 1:200 
Luciferase Goat Novus 100-1677 1:500 
Neurofilament-H Chicken Abcam AB4680 1:1000 
TuJ1 Rabbit Abcam AB18207 1:1000 
NCAM Rabbit Abcam AB75813 1:200 
Bax Rabbit Upstate 
biotechnology 
06-499 1:1000 
-actin Mouse Abcam AB8226 1:10,000 
GMCSF Mouse Abcam AB9741 1:1000 
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III. RESULTS 
 
1. Establish gene expression system in mouse neural stem cells 
Whole experiments were conducted using pGL3 based plasmid. NSE-Luci was 
constructed using neuron specific enolase (NSE) promoter and pGL3-basic plasmid. 
SV-GMCSF and NSE-GMCSF was made by substituted luciferase gene of SV-Luci 
and NSE-Luci to GM-CSF gene (Fig. 1A). 
To examine the neuronal differentiation potency of mNSCs used in this study, cells 
were cultured in differentiation media containing RA (1 μM) for 7 days. 
Differentiated cells were positive with the neuronal markers TUJ1, MAP2, NCAM, 
and neuro-filament. This result showed that cells used in this study are neural stem 
cells which can be differentiated into neurons (Fig. 1B-D). 
 Before whole experiments were conducted, transfection characteristic was confirmed. 
Because of using transient gene expression system, transfection efficiency and gene 
expression in mNSCs was tested.  
Transfection efficiency in mNSCs was measured by using DsRed expression vector. 
2 days after transfection, positive cells of DsRed or DAPI were counted and 
compared with them. The average of DsRed positive cell was 40 % percentage 
compared with DAPI (Fig. 2A).  
The target gene expression by transfected mNSCs was confirmed. After mNSCs 
were transfected with SV-GMCSF or NSE-GMCSF, the immune-fluorescence 
staining was conducted using anti-GMCSF. Although anti-GM-CSF was positive in 
mNSCs, but there didn’t show a difference between SV-GMCSF and NSE-GMCSF. 
This means that over-expressed GMC-SF was secreted extra-cellular membrane (Fig. 
2B). 
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Figure 1. Plasmid construction and characterization of mouse neural stem cells 
(A) Plasmid construction of neuronal cell type-inducible or general luciferase over-
expression vectors. The NSE promoter region was inserted to pGL3-basic vector after 
digestion (NheI and BglII sites). The mouse GM-CSF was inserted into luciferase site 
sites of neuronal cell type-inducible or general luciferase expression vector. Neuronal 
differentiation potency of mNSCs was confirmed by fluorescence staining specific for 
each neuron. (B and C) Most of the differentiated cells were positive for neuron-
specific markers such as beta-III-tubulin, MAP2, and NCAM. (D) The thick axonal 
bundle was confirmed by staining with neuro-filament and beta-III-tubulin. 
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Figure 2. Transfection efficiency and gene expression in mNSCs 
(A) The DsRed expressing plasmid was tranfected into mNSCs to examine the 
transfection efficiency in mNSCs. 2 days after transfection into mNSCs, DsRed or 
DAPI positive cells were counted. About 40 % of mNSCs were positive with DsRed 
compared with DAPI positive cells. Fluorescence scale bar, 200 m. (B) Immune-
fluorescence staining was carried out for detecting of GM-CSF expression in mNSCs 
which were transfected with SV-GMCSF or NSE-GMCSF. There are no difference 
between SV-GMCSF and NSE-GMCSF. Fluorescence scale bar, 20 m. 
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2. Expression pattern of neural stem cells transfected with a neuronal cell type-
inducible luciferase over-expression system (NSE-Luci) 
The level of luciferase expression in mNSCs was investigated which were 
transfected with Control (DsRed), SV-Luci, and NSE-Luci plasmid to confirm 
whether this neuronal cell type-inducible gene over-expression system is suitable for 
mNSCs. Based on the results of IVIS and the luciferase assay, luciferase expression 
significantly increased in NSE-Luci compared to SV-Luci (Fig. 3). These results 
indicate that the neuronal cell type-inducible transgene over-expression system is 
suitable for mNSCs.  
To identify whether the transgene over-expression pattern can be sustained after 
hypoxic injury (mimicking tissue ischemia after SCI), the luciferase expression levels 
of Control, SV-Luci, and NSE-Luci were compared after hypoxic injury for 24 h. the 
luciferase expression level significantly increased in NSE-Luci compared to that in 
SV-Luci (Fig. 3). These results indicate that the merged therapy strategy with mNSCs 
and a neuronal cell type-inducible gene over-expression system can be applied to 
spinal cord injuries that cause tissue ischemia. 
In order to assure whether the NSE was selectively working in neuronal lineage cells, 
the luciferase expression levels were examined in HEK 293FT cells, which are human 
embryonic kidney cells, transfected with Control (DsRed), SV-Luci, and NSE-Luci 
plasmid. The luciferase expression level in 293FT transfected with NSE-Luci plasmid 
was significantly lower than 293FT transfected with SV-Luci plasmid (Fig. 4). This 
result means that the efficacy of the neuronal cell-type–inducible gene expression 
system depends on neuronal lineage cell type. 
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Figure 3. Luciferase expression pattern of neural stem cells introduced with a 
neuronal cell type-inducible luciferase over-expression system (NSE-Luci) in 
normoxia and hypoxia 
Luciferase expression levels of Control, SV-Luci, and NSE-Luci were examined by 
luciferase expression imaging, the day after transfection, which were incubated at 24 
h more in normoxia or hypoxia. (A) The result of luciferase expression imaging of 
IVIS indicates that luciferase in NSE-Luci group was highly over-expressed 
compared to the other groups. The color scale bar indicates the luciferase expression 
level. (B) Quantitative analysis of luciferase expression imaging in Fig. 3A. (C) 
Luciferase expression levels of Control, SV-Luci, and NSE-Luci examined by 
luciferase assay. Luciferase expression of NSE-Luci was much higher than the other 
groups in normoxia and hypoxia. * P < 0.05. Data represent mean ± S.E.M. 
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Figure 4. Neuronal cell type-inducible luciferase gene over-expression systems in 
non-neuronal cells 
To confirm whether the NSE was selectively working in neuronal lineage cells, 
Human Embryonic Kidney 293 cells (HEK-293FT), non-neuronal cells, were 
transfected. Luciferase expression levels of SV-Luci and NSE-Luci were confirmed 
by luciferase assay at 48 h after transfection. * P < 0.05. Data represent mean ± S.E.M. 
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3. Transgene expression pattern in differentiated neuron 
In order to verify whether the luciferase expression pattern of the NSE-Luci can be 
increased after neuronal differentiation (1 μM RA) compared to neural stem cells 
stage (0 μM RA), the level of luciferase expression was compared between neural 
stem cells which were un-differentiated and differentiated neuron and also compared 
between NSE-Luci and SV-Luci after inducing neuronal differentiation. The 
luciferase expression level of NSCs transfected with NSE-Luci plasmid was much 
higher after neuronal differentiation than un-differentiation (Fig. 5). At the neuronal 
differentiation condition (1 μM RA), the luciferase expression level of NSE-Luci was 
significantly higher than that of SV-Luci (Fig. 6). 
These results mean that the transgene expression by NSE promoter was induced by 
neuronal differentiation. Thus, these findings indicate that the neuronal cell type-
inducible transgene over-expression system appropriates with NSCs which have the 
neuronal differentiation potency for merged treatment strategy.  
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Figure 5. High luciferase expression pattern after differentiation into neurons 
Induced cell differentiation with treatment of 1 M RA for 7 days after transfected 
with NSE-Luci, Luciferase expression level was compared between undifferentiated 
(without RA) and differentiated cells (with 1 M RA). (A and B) Double staining was 
conducted by using immunocytochemistry with MAP2+ (mature neuronal marker, 
Green) and Luciferase+ (Luciferase marker, Red). The positive cells by 
immunostaining were indicated by arrows. (C) The Luciferase expression level of 
differentiated neurons was compared with undifferentiated neurons by using the 
luciferase assay. Luciferase expression was significantly greater in differentiated 
neurons than in neural stem cells. * P < 0.05. Data represent mean ± S.E.M. 
 
 
 
* 
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Figure 6. A neuronal cell type luciferase expression pattern after differentiation 
into neurons 
After induced differentiation for 7 days, a neuronal cell-type luciferase expression 
system was compared with a general luciferase expression system. (A) IVIS imaging 
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indicated that NSE-Luci was over-expressed luciferase than SV-Luci. (B) Using 
Luciferase assay, the luciferase expression level of NSE-Luci after neuronal 
differentiation was significantly greater than that of SV-Luci after differentiation. * P 
< 0.05. Data represent mean ± S.E.M. 
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4. Transgene expression pattern in vivo 
To confirm whether NSE-Luci show a consistent high expression pattern in vivo, 
both SV-Luci and NSE-Luci were transplanted into the spinal cord, and carried an 
IVIS analysis and luciferase assay was carried out 24 h after transplantation. Similar 
to our results in vitro, the luciferase expression level was significantly higher in NSE-
Luci than in SV-Luci (Fig. 7A and B). These results indicated that a merged treatment 
strategy based on neuronal cell type-inducible transgene expression system and NSCs 
can be applied to spinal cord injury. 
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Figure 7. Luciferase expression pattern of neuronal cell type-inducible luciferase 
gene over-expressing neural stem cells after transplantation  
(A) To define over-expression level of luciferase gene by NSE::Luci in vivo, 
transfected mNSCs (5x105 cells/2l) were transplanted 7 days after SCI mice model. 
Luciferase expression pattern of SV-Luci and NSE-Luci confirmed by IVIS 24 h after 
cell transplantation. NSE-Luci transplanted into spinal cord showed a high luciferase 
expression compared to SV-Luci after transplantation. The color scale indicates the 
luciferase expression level, not the cell numbers in this study. (B) Luciferase 
expression pattern of SV-Luci and NSE-Luci confirmed by luciferase assay 24 h after 
cell transplantation. NSE-Luci transplanted into the spinal cord consistently showed a 
high luciferase expression pattern compared to SV-Luci after transplantation. * P < 
0.05. Data represent mean ± S.E.M. 
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5. Therapeutic Gene, GM-CSF, expression pattern of a neuronal cell-type 
inducible gene expression system (NSE-GMCSF) 
To confirm expressing therapeutic gene, luciferase gene was substituted to mouse 
GM-CSF gene which is reported that GM-CSF has the effect survival of neuronal cell 
(Fig. 1A). GM-CSF is secreted cytokine, thus mature GM-CSF will be secreted out of 
the extracellular membrane.  
The level of secreted GM-CSF was investigated in culture media for 2 days after 
transfection with the GM-CSF expression vector. The amount of GM-CSF secreted 
into the culture media was significantly increased in the supernatant of mNSCs 
transfected with NSE-GMCSF plasmids compared to mNSCs transfected with 
Control (Ds-Red) or SV-GMCSF plasmid (Fig. 8A). 
In order to examine whether the GM-CSF over-expression pattern of mNSCs with 
the neuronal cell type-inducible gene over-expression system was maintained after 
transplantation into an ischemic environment, the amount of secreted GM-CSF was 
measured by conducting ELISA after mNSCs which were transfected with NSE-
GMCSF or SV-GMCSF were cultured in hypoxia or cell-toxicity conditions 
(mimicking an ischemic environment). The GM-CSF over-expression pattern of NSE-
GMCSF was consistent in the hypoxia or cell-stress conditions (Fig. 8B and C). 
Therefore, these results demonstrate that the neuronal cell type-inducible gene over-
expression system is stable, even after replacing luciferase with GM-CSF.  
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Figure 8. NSE-GMCSF in normoxia, hypoxia and injury condition 
A day after transfection, mNSCs were incubated in (A) normoxia, (B) hypoxia and 
(C) injury condition (hypoxia + 1 % DMSO) for 1 day. The expression level of GM-
CSF was measured by conducting the GMCSF ELISA assay with the culture media 
where GM-CSF was secreted. NSE-GMCSF was higher express GM-CSF than other 
groups. * P < 0.05. Data represent mean ± S.E.M. 
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6. GM-CSF expression sustains to transplanted cell survival 
To neuronal survival, expression of GM-CSF is more sustain than Control (DsRed) 
group until neuronal differentiation. The secretion period of GM-CSF into the culture 
media has been checked after transient gene transfection was carried out. The amount 
of GM-CSF secreted in culture media was measured at 3, 5 and 7 days after 
conducting transfection with SV-GMCSF and NSE-GMCSF. The result showed that 
GM-CSF secretion was sustained for about 7 days; also, the GM-CSF over-expression 
pattern of NSE-GMCSF was sustained after 7 days (Fig. 9). 
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Figure 9. The secretion pattern of GM-CSF following transient expression 
To activate the protective effect of GM-CSF to transplanted mNSCs, highly over-
expression and continuous secretion of GM-CSF were need. The amount of GM-CSF 
secreted in culture media at 3, 5 and 7 days after transfection with SV-GMCSF and 
NSE-GMCSF. Until secretion of GM-CSF became extinct, the expression level of 
GM-CSF by NSE-GMCSF was higher sustained than SV-GMCSF. * P < 0.05. Data 
represent mean ± S.E.M. 
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7. Cell survival effect of GM-CSF in vitro 
The MTT assay was used to test the protective effect of GM-CSF in vitro. 
To compare with the effect of GM-CSF, mNSCs were incubated for 3 days with 
supernatant media of each group that had been incubated in normal conditions (Fig.  
7A). In order to induce chemical damage into mNSCs, a toxic reagent, 1 % DMSO, 
was treated to mNSCs for 1 day and then and conducted an MTT assay. The data 
show that the more the level of GM-CSF increased, more mNSCs survived (Fig. 10). 
The mNSCs treated with the supernatant media of NSC-GMCSF had the highest 
survival, compared with other groups of cells. This result indicates that GM-CSF 
affects to increase the cell viability in injury condition. 
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Figure 10. Cell survival as the effect of GM-CSF in vitro  
To confirm the protective effect of GM-CSF, mNSCs incubated with the culture 
media of each group for 3 days and then 1 % DMSO was treated 24 h for injury. Cell 
survival was measured by MTT assay. The higher the level of GM-CSF expressed by 
mNSCs, the more cell viability increased. * P < 0.05. Data represent mean ± S.E.M. 
 
 
  
- 38 - 
8. GM-CSF expression pattern and anti-apoptotic effect of NSE-GMCSF  
in vivo 
To test whether similar pattern of NSE-Luci expression can be found in vivo, injured 
mice model was divided 4 groups : Sham (Only SCI), Control (DsRed), SV-GMCSF 
and NSE-GMCSF. Each transfected group was transplanted with transfected mNSCs 
into lesion of spinal cord. Consistently, the amount of secreted GM-CSF significantly 
increased in the NSE-GMCSF group, compared to other groups (Fig. 11). This result 
demonstrated that the neuronal cell type-inducible GM-CSF expression on neural 
stem cells consistently and stably functions in vivo. The level of GM-CSF was 
showed as a unit of pg/mg of total protein.  
After confirming expression of GM-CSF in mNSCs in vivo, anti-apoptotic effect of 
GM-CSF was tested in vivo. To find out the effect of GM-CSF, the western blotting 
was performed using the apoptosis marker Bax on tissue samples collected on post-
transplantation day 4. The ratio of Bax/β-actin in each transplanted cell group was 
significantly decreased compared to the Control group. Moreover, the level for NSE-
GMCSF was decreased compared with Control and SV-GMCSF (Fig. 12A and B). 
 These results supported the conclusions of previous studies that GM-CSF has a 
direct or indirect neuro-protective effect and reduces cell apoptosis. 
  
- 39 - 
 
 
 
 
Figure 11. GM-CSF expression pattern of neuronal cell-type inducible GM-CSF 
expressing neural stem cells after transplantation 
mNSCs of each group (5x105 cell/2l) was transplanted to spinal cord injury model. 
A day after transplantation, spinal cord samples were used to ELISA assay. The 
amount of GM-CSF secreted from transplanted mNSCs, which were transfected by 
NSE-GMCSF, over-expressed compared to other groups. * P < 0.05. Data represent 
mean ± S.E.M. 
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Figure 12. The anti-apoptotic effect of GM-CSF in vivo  
4 days after transplanted mNSCs into SCI model, extracted spinal cord lysates were 
examined by western blotting with apoptotic marker, Bax. (A and B) Western blotting 
data showed that transplanted mNSCs expressed decreased levels of Bax and NSE-
GMCSF expressed highly decreased levels of Bax, compared with other groups. ** P 
< 0.01. Data represent mean ± S.E.M.  
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IV. DISCCUSION 
As one of the pathologies that appear after spinal cord injury, an ischemic 
environment in the spinal cord is caused by the destruction of blood vessels; this 
ischemic condition lasts from several days to several weeks. The survival rate of the 
stem cells transplanted into the ischemic environment would normally rapidly decline. 
Therefore, a gene and stem cell therapy platform based on neural stem cells and a 
neuronal cell-type–inducible gene expression system were designed to protect 
transplanted stem cells and the injured spinal cord. 
The gene over-expression by neuron specific enolase (NSE) promoter is already 
known as working on mature neurons. It was confirmed that the luciferase expression 
level of NSE-Luci was significantly higher than the luciferase expression level of SV-
Luci; however, the luciferase expression level of 293FT cells (used as a mean non-
neuronal cell type) transfected with NSE-Luci was significantly lower than that of 
293FT cells transfected with SV-Luci plasmid. This result means that transgene over-
expression by NSE promoter is specifically working at the neural stem cell stage. The 
previous study also investigated the difference of gene over-expression based on NSE 
promoter in between neurons and non-neuronal cells such as HEK293 and HeLa 
cells.4 In addition to, it has been known that NSE is expressed not only in mature 
neuron, but also in other immature cell types such as a neuroblastoma, small cell lung 
cancer, medullary thyroid cancer, carcinoid tumors, and melanoma.26-32 Thus, it 
suggested that NSE promoter may function extensively in neuronal lineage cells. 
NSE-Luci showed a higher luciferase expression level than that of SV-Luci under 
normoxia and hypoxia. Interestingly, the luciferase expression level of NSE-Luci in 
hypoxia was higher than that of NSE-Luci in normoxia. This result consider that the 
response of mNSCs stimulated by hypoxic condition.33-36 In addition to, the luciferase 
expression level of NSE-Luci was much higher after differentiation into neurons. All 
of these features can be used advantageously, if the luciferase used in this study were 
replaced by other therapeutic genes.  
In previous study, it was confirmed that NSCs transfected with a hypoxia-inducible 
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gene expression system should be maintained for at least 1 day under hypoxic 
conditions for transgene over-expression.3 However, the gene expression level of 
NSCs transfected with a neuronal cell type-inducible gene over-expression system 
was sufficiently greater in normoxia, namely before transplantation (saving time, as 
there is no need to wait 24 h). Thus, the high amount of secreted therapeutic protein 
may be useful for improving the survival of transplanted stem cells, as well as 
protecting the injured spinal cord from exposure to an ischemic environment. 
Subsequently, the high amount of secreted therapeutic protein from transplanted 
NSCs would be sustained under the ischemic environment and, would also increase 
further neuronal differentiation.  
As known as one of the therapeutic gene, GM-CSF is a secreted cytokine, and 
mature GM-CSF is secreted out of extracellular membranes. As examining the GM-
CSF expression pattern in cell lysates of SV-GMCSF or NSE-GMCSF by Western 
blot analysis, GM-CSF expression level of NSE-GMCSF was similar to SV-GM-CSF 
(the data was not shown). Finally, the amount of GM-CSF secreted in culture media 
was significantly increased in NSE-GMCSF. These results indicate that mature 
therapeutic protein was properly made by neural stem cells transfected with the 
neuronal cell type-inducible therapeutic gene over-expression system. The blood 
brain barrier or blood spinal cord barrier are present in the central nervous system so 
that it is very difficult to deliver a relatively large sized therapeutic protein to a lesion 
site by oral ingestion or injection. Based on this problem, direct transplantation of 
therapeutic gene expressing stem cells at the injured region of the central nervous 
system may provide the maximal therapeutic benefit by allowing a relatively large 
sized therapeutic protein to be provided directly and sustainably to the neural tissues 
or other cells.  
In this study, it has a limited part that only focused on the reproducibility regarding 
the stability or consistency of the neuronal cell type-inducible therapeutic gene over-
expression system in neural stem cells. Thus, the biological effect of the therapeutic 
gene did not further investigated. Because the transient gene transfection method was 
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used in all experiments, the secretion of GM-CSF couldn’t be expected beyond 7 days 
(Fig. 9). In future studies, it will be necessary to establish a stably therapeutic gene-
expressing neural stem cell line for long-term secretion of therapeutic protein after 
transplantation. If that happens, it could be expected that the high amount of the 
therapeutic gene secreted by therapeutic gene-expressing NSCs will be performed 
effectively their innate biological function.  
Thus, these findings suggest that a neuronal cell type-inducible gene expression 
system is suitable for use combined with NSCs for expressing a high amount of 
therapeutic genes, and such gene and neural stem cell therapy methods based on 
present systems would be very promising tools as potential treatment for spinal cord 
injury.  
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V. CONCULSION 
In this study, a combined treatment strategy using a neuronal cell type-specific 
transgene expression system with NSCs was established for spinal cord injury. It was 
confirmed that the luciferase gene expression level of NSE-Luci was significantly 
higher than that of SV-Luci. This pattern was sustained after hypoxic injury and in 
vivo. After verified by using Luciferase gene, GM-CSF gene expression level of NSE-
GM-CSF was compared with SV-GMCSF. The amount of secreted GM-CSF is 
significantly increased in the supernatant of NSCs transfected with NSE-GMCSF. 
The GM-CSF over-expression of NSE-GMCSF was consistently stable in hypoxic or 
cell stress conditions as well as in vivo. It is suggest that a neuronal cell type inducible 
transgene expression system is suitable for neural stem cells; furthermore, a combined 
treatment strategy based on a neuronal cell type-inducible therapeutic gene over-
expression system and NSCs may provide an effective therapeutic outcome for 
neurological disease treatment. 
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ABSTRACT (IN KOREAN) 
 
척추신경손상모델에서 신경계열 세포 특이적 유전자 발현시스템과 
신경줄기세포를 이용한 병합 치료 기술 개발 
 
<지도교수 하 윤> 
 
연세대학교 대학원 의과학과 
 
유 영 상 
 
영구적인 신경손상과 관련된 척수 손상 치료에 있어서 유망한 치
료기술이 필요하다. 단일 치료 기술로 충분한 치료효과를 기대하기 
힘들기에 두 가지 이상 병합된 치료 기술이 치료 효과를 보다 향상 
시킬 수 있을 것이다.  
본 연구에서, 치료 효율을 극대화하고자 신경세포 계열 특이적인 
프로모터로 조절되는 신경세포 계열 특이적 발현시스템과 신경줄기
세포 병합 기술을 개발하였다. 치료유전자를 사용하기 전에 병합 시
스템이 적절히 작동하는지 확인하고자 루시퍼레이즈 유전자를 선택
하여 신경 세포 계열 특이적 유전자 발현시스템 (NSE-Luci)과 신경
세포 계열 비특이적 유전자 발현시스템 (SV-Luci)을 생체 내와 생체 
외 조건에서 비교 분석하였다. 루시퍼레이즈 유전자로 신경세포계열 
특이적 유전자 발현시스템을 확인 한 뒤, 치료유전자인 과립대식세
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포 자극인자 발현 시스템을 제작하였으며 생체 내와 생체 외 조건에
서 신경세포 계열 특이적 발현시스템을 비교하였다.  
실험 결과로 신경줄기세포에 도입된 신경세포계열 특이적 유전자 
발현 시스템이 비특이적 유전자 발현시스템보다 루시퍼레이즈 유전
자가 과발현되는 것을 확인하였고 또한 치료유전자 발현시스템에서 
과립대식세포 자극인자가 과발현되는 것을 확인하였다.  
신경세포 계열 비특이적 유전자 발현시스템보다 신경 세포 계열 
특이적 유전자 발현시스템이 신경 줄기 세포와 병합 치료 기술에 
있어서 적합하다는 것을 증명해보았다. 따라서, 척수손상과 같은 
신경퇴행성 질환 치료에 있어서 이와 같은 병합치료기술이 유용한 
기법으로 사용될 수 있음을 제안을 해본다. 
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